Literature DB >> 17215125

Molecular biology of PCSK9: its role in LDL metabolism.

Jay D Horton1, Jonathan C Cohen, Helen H Hobbs.   

Abstract

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17215125      PMCID： PMC2711871          DOI： 10.1016/j.tibs.2006.12.008

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN： 0968-0004            Impact factor:   13.807


  44 in total

1.  A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.

Authors:  Kirsten M Timms; Susanne Wagner; Mark E Samuels; Kristian Forbey; Howard Goldfine; Srikanth Jammulapati; Mark H Skolnick; Paul N Hopkins; Steve C Hunt; Donna M Shattuck
Journal:  Hum Genet       Date:  2004-01-15       Impact factor: 4.132

2.  Biomedicine. Lowering LDL--not only how low, but how long?

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  Science       Date:  2006-03-24       Impact factor: 47.728

3.  Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.

Authors:  Steve Poirier; Annik Prat; Edwige Marcinkiewicz; Joanne Paquin; Babykumari P Chitramuthu; David Baranowski; Benoit Cadieux; Hugh P J Bennett; Nabil G Seidah
Journal:  J Neurochem       Date:  2006-08       Impact factor: 5.372

4.  The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.

Authors:  Suzanne Benjannet; David Rhainds; Josée Hamelin; Nasha Nassoury; Nabil G Seidah
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

5.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

6.  The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.

Authors:  Amanda J Hooper; A David Marais; Donald M Tanyanyiwa; John R Burnett
Journal:  Atherosclerosis       Date:  2006-09-20       Impact factor: 5.162

7.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

Authors:  Zhenze Zhao; Yetsa Tuakli-Wosornu; Thomas A Lagace; Lisa Kinch; Nicholas V Grishin; Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-07-18       Impact factor: 11.025

8.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

9.  Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.

Authors:  T P Leren
Journal:  Clin Genet       Date:  2004-05       Impact factor: 4.438

10.  Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.

Authors:  Livia Pisciotta; Claudio Priore Oliva; Angelo Baldassare Cefalù; Davide Noto; Antonella Bellocchio; Raffaele Fresa; Alfredo Cantafora; Dilip Patel; Maurizio Averna; Patrizia Tarugi; Sebastiano Calandra; Stefano Bertolini
Journal:  Atherosclerosis       Date:  2005-09-23       Impact factor: 5.162
View more
  185 in total

1.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Authors:  Mali Liu; Guoxin Wu; Jennifer Baysarowich; Michael Kavana; George H Addona; Kathleen K Bierilo; John S Mudgett; Guillaume Pavlovic; Ayesha Sitlani; John J Renger; Brian K Hubbard; Timothy S Fisher; Celina V Zerbinatti
Journal:  J Lipid Res       Date:  2010-05-07       Impact factor: 5.922

2.  Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people.

Authors:  Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein
Journal:  Transl Res       Date:  2011-07-19       Impact factor: 7.012

3.  LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring.

Authors:  Portia Ritter; Keyvan Yousefi; Juliana Ramirez; Derek M Dykxhoorn; Armando J Mendez; Lina A Shehadeh
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

4.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

5.  PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.

Authors:  Xiaohui Xu; Yushang Cui; Lei Cao; Ye Zhang; Yan Yin; Xue Hu
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

6.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Authors:  Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

7.  Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements.

Authors:  Hai Li; Wei Chen; Yue Zhou; Parveen Abidi; Orr Sharpe; William H Robinson; Fredric B Kraemer; Jingwen Liu
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

8.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

9.  Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.

Authors:  Amar Bahadur Singh; Bin Dong; Fredric B Kraemer; Yanyong Xu; Yanqiao Zhang; Jingwen Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

10.  Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.

Authors:  Bin Dong; Mark Young; Xueqing Liu; Amar Bahadur Singh; Jingwen Liu
Journal:  J Lipid Res       Date:  2016-12-09       Impact factor: 5.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.